Cargando…
Harms in Systematic Reviews Paper 3: Given the same data sources, systematic reviews of gabapentin have different results for harms
OBJECTIVE: In this methodologic study (Part 2 of 2), we examined the overlap in sources of evidence and the corresponding results for harms in systematic reviews for gabapentin. STUDY DESIGN & SETTING: We extracted all citations referenced as sources of evidence for harms of gabapentin from 70 s...
Autores principales: | Qureshi, Riaz, Mayo-Wilson, Evan, Rittiphairoj, Thanitsara, McAdams-DeMarco, Mara, Guallar, Eliseo, Li, Tianjing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875741/ https://www.ncbi.nlm.nih.gov/pubmed/34742790 http://dx.doi.org/10.1016/j.jclinepi.2021.10.025 |
Ejemplares similares
-
Harms in Systematic Reviews Paper 2: Methods used to assess harms are neglected in systematic reviews of gabapentin
por: Qureshi, Riaz, et al.
Publicado: (2022) -
Summaries of harms in systematic reviews are unreliable Paper 1: An introduction to research on harms
por: Qureshi, Riaz, et al.
Publicado: (2022) -
Comparing the Value of Data Visualization Methods for Communicating Harms in Clinical Trials
por: Qureshi, Riaz, et al.
Publicado: (2022) -
Conducting separate reviews of benefits and harms could improve systematic reviews and meta-analyses
por: Mayo-Wilson, Evan, et al.
Publicado: (2023) -
Probiotics for glycemic control in patients with type 2 diabetes mellitus: protocol for a systematic review
por: Rittiphairoj, Thanitsara, et al.
Publicado: (2019)